Solid Biosciences (SLDB) Accumulated Expenses (2017 - 2024)
Historic Accumulated Expenses for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $13.2 million.
- Solid Biosciences' Accumulated Expenses rose 1535.85% to $13.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $13.2 million, marking a year-over-year increase of 1535.85%. This contributed to the annual value of $10.2 million for FY2023, which is 3912.29% down from last year.
- As of Q3 2024, Solid Biosciences' Accumulated Expenses stood at $13.2 million, which was up 1535.85% from $9.9 million recorded in Q2 2024.
- Over the past 5 years, Solid Biosciences' Accumulated Expenses peaked at $16.7 million during Q4 2022, and registered a low of $6.8 million during Q1 2021.
- In the last 5 years, Solid Biosciences' Accumulated Expenses had a median value of $9.9 million in 2024 and averaged $10.3 million.
- As far as peak fluctuations go, Solid Biosciences' Accumulated Expenses surged by 10924.29% in 2022, and later crashed by 3912.29% in 2023.
- Solid Biosciences' Accumulated Expenses (Quarter) stood at $8.6 million in 2020, then grew by 10.28% to $9.5 million in 2021, then surged by 75.18% to $16.7 million in 2022, then crashed by 39.12% to $10.2 million in 2023, then soared by 30.17% to $13.2 million in 2024.
- Its Accumulated Expenses stands at $13.2 million for Q3 2024, versus $9.9 million for Q2 2024 and $10.3 million for Q1 2024.